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ABSTRACT
This retrospective study aimed to investigate the role that an RNA-binding
protein, HuR, plays in the response of high-grade serous ovarian tumors to
chemotherapeutics. We immunohistochemically stained sections of 31 surgicallydebulked chemo-naïve ovarian tumors for HuR and scored the degree of HuR
cytoplasmic staining. We found no correlation between HuR intracellular localization
in tumor sections and progression free survival (PFS) of these patients, 29 of whom
underwent second-line gemcitabine/platin combination therapy for recurrent disease.
Ribonucleoprotein immunoprecipitation (RNP-IP) analysis of ovarian cancer cells
in culture showed that cytoplasmic HuR increases deoxycytidine kinase (dCK), a
metabolic enzyme that activates gemcitabine. The effects of carboplatin treatment
on HuR and WEE1 (a mitotic inhibitor) expression, and on cell cycle kinetics, were
also examined. Treatment of ovarian cancer cells with carboplatin results in increased
HuR cytoplasmic expression and elevated WEE1 expression, arresting cell cycle G2/M
transition. This may explain why HuR cytoplasmic localization in chemo-naïve tumors
is not predictive of therapeutic response and PFS following second-line gemcitabine/
platin combination therapy. These results suggest treatment of recurrent ovarian
tumors with a combination of gemcitabine, carboplatin, and a WEE1 inhibitor may be
potentially advantageous as compared to current clinical practices.

combination with carboplatin is commonly used as a
second-line chemotherapy to treat recurrent disease. Some
tumors respond better to a combination of gemcitabine and
carboplatin than others, resulting in longer progression
free survival (PFS). Unfortunately, the field does not have
a reliable biomarker to determine which patients will
respond well. Even when patients respond to the most
aggressive therapy, almost all will eventually succumb to
their disease.

INTRODUCTION
Nearly 80% of ovarian cancer patients will have
a favorable response to first-line therapy consisting
of optimal surgical debulking followed by aggressive
chemotherapy with paclitaxel and a platinum-based
therapy [1]. Unfortunately, due to the development of
chemoresistant disease, a majority of patients will develop
recurrent tumors within 16-22 months. Gemcitabine in
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Gemcitabine acts as a prodrug that, when
metabolized to gemcitabine di- and tri-phosphates,
functions to inhibit DNA elongation, DNA repair enzymes,
and RNA synthesis [2, 3]. Potential clinical relevance of an
association between the amount of cytoplasmic localization
of an RNA-binding protein, HuR, in tumor cells and the
metabolic activation of gemcitabine has recently been
identified [4, 5]. HuR functions in normal, healthy cells
as a critical molecule involved in post-transcriptional
gene regulation. When cells are stressed, e.g., by low
oxygen levels, HuR potently influences translation of key
survival and growth-related mRNAs in the cytoplasm by
several mechanisms including active transport of mRNAs
from the nucleus to the cytoplasm, mRNA stabilization,
and direct facilitation of translation. In line with these
functions, HuR has been identified as a marker for poor
prognosis in many cancers, including ovarian cancer
[6–8]. In two small cohorts of pancreatic cancer patients
treated with gemcitabine following surgery, a significant
association between increased overall survival and high
HuR expression in the cytoplasm has been identified,
suggesting that HuR subcellular localization might serve
as a predictive marker for gemcitabine response [4, 5].
Enhanced gemcitabine functionality in tumors is likely the
consequence of increased production of the key nucleoside
analog metabolizing enzyme, deoxycytidine kinase (dCK)
resulting from post-transcriptional regulation of dCK
mRNA by HuR [4, 5, 9, 10]. In this study, we sought,
but found no evidence, that HuR cellular localization
might serve as a predictive marker for clinical outcome
following gemcitabine treatment of recurrent ovarian
tumors. We explored potential reasons why this might be
the case. The results of our findings suggest that improved
clinical outcomes for ovarian cancer patients might be
better achieved using gemcitabine in combination with
carboplatin and a WEE1 inhibitor as a second-line therapy.

more chemotherapeutics – 26 with carboplatin, 1 with
carboplatin and avastin, and 2 with cisplatin (Table 1).
Two of the 31 tumors had HuR expression in only a few
nuclei and no cytoplasmic HuR, 1/30 had only nuclear
staining, while HuR was present in at least 50% of nuclei
and in the cytoplasm of 28/30 tumors. The amount of
cytoplasmic HuR in these 28 tumors varied: 7 were
scored +/-, 9 were +, 6 were ++, and 6 were +++ (Figure
1B). To assess whether the amount of cytoplasmic HuR
expression in tumors was predictive of PFS following
gemcitabine/carboplatin, we compared PFS of patients
whose tumors had low cytoplasmic HuR expression (-,
+/-, +; n=19; median = 8 mo) with that of patients whose
tumors had high cytoplasmic HuR expression (++ and
+++; n=12; median = 8 mo) (Figure 1C). There was no
significant difference in PFS (p=0.58). Even when tumors
that were scored as + were grouped with ++ and +++
tumors, there was no significant difference in PFS (- and
+/-; n=9; median = 8 mo) and (+, ++, +++; n=22; median
= 8 mo) (p=0.62). The two tumor specimens that were
collected after first-line therapy had cytoplasmic HuR
scores of + and +++, and had PFS values of 3 mo and 4
mo, respectively. The PFS of the 3 patients whose tumors
had no detectable HuR in the cytoplasm was near or
above the median value (8 mo, 8 mo, 12 mo). These data
provide no evidence to support the use of HuR subcellular
localization as a predictive marker for ovarian tumor
sensitivity to second line treatment with gemcitabine. We
note, however, a correlation of lower tumor grades (Grades
I and II) with low cytoplasmic HuR, and Grade III tumors
with high cytoplasmic HuR approached significance
(p=0.066) (Figure S1).
Patients in this study were treated with different
numbers of cycles of carboplatin/paclitaxel (1X, n=18; 2X,
n=7; 3X, n=2; 4X, n=3; 5X, n=5), thereby contributing
variability to the duration of first-line carboplatin/
paclitaxel therapy and the time between assessment of
HuR localization status in surgically-debulked tumors
and the initiation of gemcitabine treatment. In addition,
patients were treated with different numbers of cycles
of gemcitabine as second-line therapy (range 2-11),
with most patients treated 5 (n=8) or 6 (n=11) times,
and with gemcitabine in combination with different
chemotherapeutic drugs. These variables may contribute to
our failure to identify a correlation between HuR cellular
localization in ovarian tumors and PFS as was observed
in pancreatic adenocarcinoma where gemcitabine is
administered to patients as a first-line therapy. We
investigated possible molecular mechanisms that might
be operative in the context of these variables.

RESULTS AND DISCUSSION
Is HuR cellular localization in ovarian tumors
predictive of favorable tumor response to
gemcitabine?
We investigated whether there is a correlation
between subcellular localization of HuR in tumor cells
and PFS of ovarian cancer patients receiving gemcitabine
as a second-line therapy for recurrent tumors. Sections of
thirty-one ovarian tumor specimens from patients treated
with gemcitabine were immunostained for HuR. Twentynine of the specimens were from chemo-naive tumors (i.e.,
surgically-debulked tumors prior to any chemotherapy),
while two were from secondary surgically-debulked
tumors following first-line chemotherapy with carboplatin
and paclitaxel (Figure 1A). Twenty-nine of the 31 tumor
specimens were from patients receiving second-line
therapy with gemcitabine in combination with one or
www.impactjournals.com/oncotarget
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deoxyribonucleosides as well as their nucleoside
analogs (e.g., gemcitabine) [11]. To confirm that dCK
activates gemcitabine in ovarian cancer cells, as has been
demonstrated in pancreatic cancer cells [4], we transiently
transfected A2780 cells with siRNA against dCK
(siDCK) or siControl (siCtrl) for 24 h, then treated cells
with various concentrations of gemcitabine for 48 h and
measured viable cells. In parallel cultures, we confirmed
dCK suppression in siDCK-transfected cells by western
blot analysis (Figure S2). dCK inhibition resulted in ~80%
increase in cell number when cells were treated with 0.005
and 0.01 μM gemcitabine as compared to gemcitabinetreated siCtrl-transfected and untransfected cells (p<0.005)
(Figure S2). These results support gemcitabine activation
by dCK in ovarian cancer cells.

and to competition with miRNAs for binding sites [12–
16]. We have shown that, upon gemcitabine treatment,
HuRbinds to dCK mRNA in pancreatic tumor cells,
resulting in increased dCK protein and activity [4]. In
addition, we have shown a strong correlation between
dCK and HuR cytoplasmic expression in pancreatic
ductal adenocarcinomas [9]. Our recent studies identified
specific mRNAs bound to HuR in ovarian and pancreatic
cancer cells that are unique to these two cancer types [17,
18]. It is therefore possible that HuR may not directly
associate with dCK mRNA in ovarian cancer cells as it
does in pancreatic cancer cells, thereby offering a possible
explanation why HuR cytoplasmic localization failed to
serve as an informative marker for gemcitabine sensitivity.
To test whether HuR translocation from the nucleus to the
cytoplasm in response to gemcitabine correlates with an
increase in dCK expression in ovarian cancer cells, we
treated OVCAR5 cells with 0.02 μM gemcitabine (IC50),
prepared cytoplasmic and nuclear protein fractions at
various time points, and analyzed the amount of HuR
and dCK proteins in these two cellular compartments on

HuR binds to dCK mRNA in ovarian cancer cells
HuR protein binds to specific mRNA transcripts
in a highly regulated process subject to modifications of
HuR protein itself (e.g., phosphorylation and methylation)

Figure 1: Analysis of HuR subcellular localization in ovarian tumor specimens and corresponding progression free
survival of patients. A. Treatment protocol for ovarian cancer patients with recurrent tumors. B. Ovarian tumor sections immunostained for
HuR and representative of how staining intensity was scored. C. Kaplan-Meier plot of progression free survival (PFS) of patients with tumors
having relatively low HuR cytoplasmic staining (scored -, +/-, or +) and tumors having high cytoplasmic HuR staining (scored ++ or +++).
www.impactjournals.com/oncotarget
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Table 1: Profile of patients in this study
Age (yrs)

61.8 +/- 9.3*

Race

Caucasian (29)
African American (2)

Stage

Ib (1)
Ic (1)
II (1)
IIb (1)
IIc (1)
IIIb (1)
IIIc (24)
unstaged (1)

Grade

g2 (4)
g2-3 (3)
g3 (24)

Histology

serous (27)
serous/endometrioid (1)
serous w/mucinous features (1)
carcinosarcoma + serous (1)
serous w/clear cell features (1)

Optimal debulking

20 optimal
11 sub-optimal

# first-line therapy carboplatin + paclitaxel cycles

1.8 +/- 1.1* (range: 1-5)

# second-line gemcitabine cycles
(i.e., treatment of recurrent tumors)

5.1 +/- 1.9* (range: 3-11)

Second-line gemcitabine therapy
combined with other chemo?

Carboplatin (26)
Carboplatin + avastin (1)
Cisplatin (2)
None (2)

Progression Free Survival (mo)

8.5 +/- 4.8* (range: 3-26)

*Mean +/- S.D.
western blots. Cytoplasmic HuR and dCK levels peaked
between 16 h and 48 h after gemcitabine treatment (~1.5fold higher than level at 0 h) (Figure 2A). An increase in
dCK mRNA was also observed by qRT-PCR during this
timeframe (Figure 2B). Increased cytoplasmic HuR at
48 h after gemcitabine treatment was also observed by
immunofluorescent staining (Figure 2C). The amount
of nuclear HuR, however, appeared unchanged upon
gemcitabine treatment (Figure 2A), most likely due to
masking of subtle changes in its abundance that are not
detected on western blots. The same analysis of another
ovarian cancer cell line, A2780, confirmed the association
of gemcitabine-induced elevation of cytoplasmic HuR
and dCK mRNA/protein (Figure S3). Sections of human
ovarian tumors immunostained for HuR and dCK revealed
a positive correlation (p=0.008) between cytoplasmic
HuR expression and dCK expression (Figure 2D). These

www.impactjournals.com/oncotarget

results show that gemcitabine treatment induces HuR
translocation to the cytoplasm and that this translocation
is associated with increased dCK expression in ovarian
cancer cells.
The dCK 3’UTR region contains 8 putative HuR
recognition motifs [19]. To determine whether HuR
binds directly to dCK mRNA in ovarian cancer cells, we
performed RNP-IP assays on lysates prepared from A2780
cells grown in the presence or absence of gemcitabine for
12 hours. An RNP-IP with a HuR-specific antibody was
performed to isolate total mRNA transcripts associated
with HuR, followed by qRT-PCR to determine the amount
of dCK mRNA associated with HuR protein. IgG RNP-IP
was performed as a negative control (Figure 3). The dCK
mRNA level was increased 4-fold in gemcitabine-treated
cells compared to untreated cells. SUMO-1 mRNA, a
HuR target (unpublished, Brody Lab), served as a positive
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Figure 2: HuR nuclear to cytoplasmic translocation following treatment of OVCAR5 cells with gemcitabine (GEM)
associated with an increase in cytoplasmic dCK mRNA and protein. A. Western blot analysis for HuR and dCK in cytoplasmic

and nuclear protein lysates. GAPDH provided loading control and allowed for quantitative comparison of HuR and dCK at different time
points (values indicated beneath HuR and dCK panels). Lamin A/C provides marker for cytoplasmic extract purity. B. qRT-PCR analysis
of cytoplasmic dCK mRNA isolated from OVCAR5 cells treated with GEM for different times (mean +/- SD). C. OVCAR5 cells grown
in medium +/- GEM and immunostained for HuR. White arrows point to cytoplasmic HuR. D. Sections of human ovarian tumor, collected
prior to drug treatment, were immunostained for HuR and dCK. Boxed area is enlarged in lower left corner of each panel in top row.

Figure 3: RNP-IP assays showing increased binding of dCK mRNA to HuR in response to gemcitabine. A. HuR proteinbound dCK (left) and SUMO-1 (right) mRNA amounts in A2780 cells grown in the presence or absence of 1μM GEM for 12 h as measured
by qPCR (mean +/- SD). B. Left: Western blots of protein lysates prepared from A2780 cells grown in the presence or absence of 1 μM
GEM, before immunoprecipitation, and immunoprecipitates prepared with anti-HuR. Three separate IPs were assayed. Right: Western blots
of protein lysates before immunoprecipitation, and immunoprecipitates prepared with IgG.
www.impactjournals.com/oncotarget
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control and was enriched ~2 fold upon gemcitabine stress
(Figure 3). The same study performed in OVCAR3 cells
confirmed the observation that dCK mRNA isolated from
HuR RNP-IP samples were significantly enriched (Figure
S4). These results indicate that HuR binds directly to dCK
mRNA in ovarian cancer cells, just as it does in pancreatic
cancer cells.

(shHuR) [17]. We stressed OVCAR5, OVCAR5-shCtrl,
and OVCAR5-shHuRc257 cells with 0.02 μM gemcitabine
for 0, 6, 12, 24, 48, and 72 h, then prepared whole cell
lysates to measure dCK expression on western blots
(Figure 4). dCK protein expression in gemcitabine-treated
OVCAR5 and OVCAR5-shCtrl cells increased (35-84%)
in a time dependent manner (Figure 4). In contrast, dCK
expression in gemcitabine-treated OVCAR5-shHuRc257
cells remained unchanged at all time points except 72
h when a minor increase was observed (Figure 4). A
small increase in total HuR expression was observed in
gemcitabine-treated OVCAR5-shHuRc257 cells. This
observation likely reflects previous reports of HuR selfregulation [20–22].

HuR suppression reduces dCK expression and
gemcitabine efficacy
To study HuR regulation of dCK further, we
examined the effect of HuR silencing on dCK expression.
We generated an ovarian cancer cell line, OVCAR5shHuRc257 that stably expresses short hairpin RNA

Figure 4: HuR suppression inhibits increase in dCK expression in response to GEM. Western blot analysis of HuR and dCK
protein expression in OVCAR5, OVCAR5-shCtrl, and OVCAR5-shHuR cells treated with or without 0.02 μM gemcitabine (GEM) for
indicated times.
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Combination chemotherapy abrogates HuR’s
ability to act as a predictive marker for
gemcitabine efficacy

Next, we determined the impact of HuR inhibition
on ovarian cancer cell sensitivity to gemcitabine.
We treated two cell lines, OVCAR5-shHuRc257
and OVCAR3-shHuRi699, a doxycycline (DOX)inducible HuR-targeted shRNA ovarian cancer cell
line, with various gemcitabine concentrations for 72
h, and then assessed cell viability. HuR suppression in
OVCAR5-shHuRc257 and DOX-induced OVCAR3shHuRi699 cells compared to control cells resulted in
reduced sensitivity to gemcitabine (Figure 5). In sum,
these experiments show that HuR translocation to the
cytoplasm in response to gemcitabine exposure results
in increased dCK expression. This, in turn, results in
enhanced gemcitabine therapeutic efficacy in ovarian
cancer cells. It is clear that there must be another
confounding factor or factors that compromise the value
of HuR cellular localization as a predictive marker of
second-line gemcitabine efficacy.

Nearly all of the tumor samples examined in
our patient study (29/31) were obtained from surgical
debulking procedures performed prior to first-line
carboplatin/paclitaxel treatment. Given our previous
study in which we showed HuR translocation from the
nucleus to the cytoplasm in pancreatic cancer cells upon
stress with DNA-damaging anticancer agents including
carboplatin and paclitaxel [23], it is reasonable to expect
an increase in cytoplasmic HuR in response to exposure
to first-line treatment, far in advance of gemcitabine/
carboplatin second-line therapy. The fact that 12/29
of the tumors had significant cytoplasmic HuR prior to
first-line therapy, and the PFS of these patients was not
significantly different from that of patients with low
cytoplasmic HuR, is further evidence that the complexity

Figure 5: HuR suppression reduces gemcitabine chemotherapeutic efficacy. A. Number of OVCAR5-shCtrl or OVCAR5-

shHuR cells at 72 h following treatment with different concentrations of GEM. Western blot analysis of HuR of whole cell lysates in
OVCAR5-shCtrl or OVCAR5-shHuR cells (mean +/- SD). B. Numbers of OVCAR3-shHuRi699 cells treated with +/- 0.1μg/ml DOX and
with different GEM concentrations. Western blot analysis of HuR in OVCAR3-shHuRi699 cultured in GEM-containing medium with or
without DOX (mean +/- SD). shHuRi = inducible shHuR; shHuRc = constitutively expressed shHuR. *indicates p<0.05
www.impactjournals.com/oncotarget
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of HuR biology abrogates its use as a predictive marker
for efficacy of gemcitabine second-line therapy. Ideally, it
would be preferable to determine HuR status just prior to
gemcitabine therapy, but surgical debulking of recurrent
tumors is rarely performed, limiting the clinical feasibility
of attaining tumor specimens.
Another complication is that gemcitabine is
nearly always administered to ovarian cancer patients in
combination with one or more chemotherapeutics, usually
carboplatin. A recent study showed that DNA-damaging
radiation therapy, given in combination with gemcitabine,
may disrupt HuR’s ability to act as an informative
biomarker (9). Expression of WEE1, a mitotic inhibitor
kinase that regulates the DNA damage repair pathway, is
present in ovarian cancer ascites following chemotherapy
[24]. We have shown that an increase in HuR in response
to DNA-damaging chemotherapeutics (e.g., carboplatin)
results in elevated WEE1 in pancreatic cancer cells [23].
Elevated Wee1, in turn, promotes cell-cycle arrest at the
G2/M transition and ensuing resistance to DNA-damaging
agents. To explore whether HuR regulation of WEE1
provides a mechanism underlying the lack of improved
PFS associated with cytoplasmic HuR in ovarian tumors

of patients treated with a combination of gemcitabine
and carboplatin, we first assayed HuR expression in
OVCAR5 cells treated with 7.5 µM carboplatin (IC50) for
various times. Cytoplasmic HuR began to increase after
24 h treatment with carboplatin and reached a maximum
increase of 1.6-fold higher than in non-treated cells at 48
h (Figure 6A). The amount of nuclear HuR remained high
in treated cells at all time points. WEE1 expression also
increased in carboplatin-treated OVCAR5 cells, reaching
a peak expression at 48 h, similar to HuR, whereas no
increase in WEE1 was observed in carboplatin-treated
OVCAR5-shHuR cells in which HuR expression was
significantly inhibited (Figures 6A-6D). WEE1 protein
increased 1.3-fold in HuR-expressing OVCAR5-shCtrl
cells upon carboplatin treatment (Figure 6B & 6C).
We also determined the effect of HuR-regulated
WEE1 expression on cell-cycle kinetics in the context of
carboplatin treatment (Figures S5A & B). We observed
that a higher percentage of cells accumulated in the G2/M
phase in OVCAR5-shCtrl cells (29.5%) as compared to
OVCAR5-shHuR (22.3%) 48 h after 7.5 µM carboplatin
treatment (Figure S5B). Under normal culture conditions,
the percentage of OVCAR5-shCtrl and OVCAR5-shHuR

Figure 6: Cytoplasmic HuR increase in response to carboplatin increases WEE1 expression. A. Western blot analysis of

HuR and WEE1 proteins in OVCAR5 cells treated with 7.5 μM carboplatin for various times (0-72 h). Cytoplasmic and nuclear extracts
were analyzed separately for HuR expression. GAPDH (a cytoplasmic marker) and Lamin A/C (a nuclear marker) analysis was also done
to evaluate purity of cytoplasmic and nuclear extract preparations. B. WEE1 expression in OVCAR5 cells stably transfected with shHuR or
with shCtrl (whole cell extracts). C. Cytoplasmic HuR and WEE1 expression in OVCAR5 cells treated with carboplatin for various times.
Numbers in panels A and B indicate expression levels of HuR and WEE1 normalized to GAPDH. D. Sections of human ovarian tumor, with
high (left) and low (right) HuR and WEE1 expression collected prior to drug treatment, immunostained for HuR and WEE1.
www.impactjournals.com/oncotarget
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cells in the G2/M phase is similar (Figure S5B). In
agreement with these in vitro observations, human ovarian
tumor sections immunostained for HuR and WEE1
revealed a positive correlation between cytoplasmic HuR
expression and WEE1 expression (p=0.048) (Figure
6D). These results offer a mechanism to explain why
cytoplasmic localization of HuR is not predictive of a
favorable outcome to gemcitabine treatment in our study
when given as a combination therapy with carboplatin.
Since arrest of DNA replication by insertion of
the gemcitabine analogue metabolite, triphosphate
cytosine, is dependent on cell division, its effectiveness
is likely to be compromised to some degree in cell cyclearrested carboplatin-treated cells even though dCK
metabolizes gemcitabine as a consequence of elevated
HuR cytoplasmic expression. Clinical experience clearly
shows, however, that in ovarian cancer patients with
platinum-sensitive relapse, progression-free survival is
prolonged when gemcitabine is given in combination with
carboplatin as compared to carboplatin monotherapy [25].
Evidence suggests that this synergy may result from the
inhibition of repair of platinum-induced DNA cross-links
by gemcitabine [26, 27]. Our results suggest that patients
with recurrent tumors be treated first with gemcitabine

followed by treatment with carboplatin. To test directly the
effect of WEE1-mediated cell cycle arrest on gemcitabine
efficacy, we measured survival of OVCAR5 cells grown in
medium containing various concentrations of gemcitabine
in the presence or absence of siWEE1. WEE1 inhibition
increased the sensitivity of cells to gemcitabine 2-4 fold
over the range of tested gemcitabine concentrations, and
decreased the IC50 from 0.02 to 0.004 μM (Figure 7). This
result suggests that it may also be advantageous to combine
inhibition of WEE1 with gemcitabine andcarboplatin as
a combination second-line therapy, thereby overcoming
cell-cycle arrest and enhancing the therapeutic response
to gemcitabine in patients with platinum-sensitive relapse.
A small molecule WEE1 inhibitor, MK-1775, has been
shown to enhance antitumor efficacy of p53-deficient
tumor cells to DNA-damaging agents including cisplatin,
carboplatin, gemcitabine and 5-fluorouracil [28–30], and
a Phase II clinical trial (NCT02101775) testing MK-1775
in combination with gemcitabine to treat recurrent ovarian
cancer is currently recruiting. Given our understanding of
how gemcitabine affects tumor cell survival, addition of
gemcitabine to this therapeutic strategy may have added
benefit to all patients independent of p53 status.

Figure 7: WEE1 inhibition sensitizes OVCAR5 cells to gemcitabine. A. OVCAR5 cells were transfected with siWEE1 or siCtrl

for 6 h. Following addition of gemcitabine at various concentrations to the culture medium, cell viability was assayed after 72 h. B. Western
blot of WEE1 in gemcitabine-treated OVCAR5 cells treated with siHuR or siCtrl. α-tubulin serves as a gel loading control. *indicates
p<0.0001
www.impactjournals.com/oncotarget
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Cell Culture, transfection, chemo-treatment, and
viability assay

One limitation of our study is that HuR localization
was analyzed in only one ovarian cancer subtype, serous
ovarian tumors, a large majority of which were high-grade
tumors. While this subtype accounts for ~70% of ovarian
tumors, these tumors differ from other tumor subtypes
(endometrial, clear cell, mucinous) not only in morphology
but also in gene expression profile, molecular genetic
features, genetic and epidemiologic risk factors, precursor
lesions, pattern of spread, and of particular relevance to
this study, response to platinum-taxane based treatment
[31, 32]. Indeed, expression of hENT1, dCK, 5’NT, and
RRM1 was found to be higher in undifferentiated and
clear cell carcinoma as compared to serous ovarian tumors
[33]. Given these substantial differences, the possibility
that HuR localization might be an informative marker for
gemcitabine response in other ovarian tumor subtypes
warrants further study.

OVCAR5 cells (A. Klein-Szanto, Fox Chase
Cancer Center) and A2780 cells (T. Hamilton, Fox Chase
Cancer Center) were maintained in RPMI-1640 medium
(Cellgro) supplemented with 10% FBS (Gemini) at
37°C in 5% CO2. OVCAR3 cells were purchased from
American Type Culture Collection (ATCC) and grown
in media as recommended by ATCC. All cells tested
negative for mycoplasma using a PCR kit (Sigma
#MP0035-1KT). For in vitro transfection, cells were
transiently transfected with siDCK (Ambion #4390824),
siWEE1 (Thomas Scientific Dharma #GLEKC-000008),
or siControl (Ambion #AM4611) using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s
directions. To determine effects of gemcitabine on HuR
and dCK expression, or carboplatin on HuR and WEE1
expression, cells were incubated in IC50 concentrations
of gemcitabine (0.02 μM) or in carboplatin (7.5 μM)
for various times, then harvested for Western blot
analysis. To determine effects of gemcitabine on HuR
knockdown cell proliferation, OVCAR5-shHuRc257
cells were incubated with various concentrations of
gemcitabine for 72 hours and OVCAR3-shHuRi699 cells
were incubated with 1µg/ml doxycycline and various
concentrations of gemcitabine for 72 hours, after which
viable cell number was determined using EZ Count Kit
(Rockland #KLD-001). All cell viability assays were
done in triplicate.

MATERIALS AND METHODS
Patient population
Medical records from our gynecologic oncology
practice (CJD) at the Lankenau Medical Center,
Wynnewood, PA, were reviewed to identify ovarian
cancer patients who had undergone surgical debulking and
first-line treatment with carboplatin and paclitaxel, who
subsequently developed recurrent tumors and underwent
further therapy with gemcitabine in combination with
carboplatin (26/31) or other chemotherapeutic (3/31).
Using patients’ medical record numbers to assure sample
de-identification, archival paraffin blocks of tumor
tissue from 31 patients were retrieved and sections were
prepared. This protocol was approved by the Lankenau
Medical Center Institutional Review Board. The patient
profile is summarized in Table 1 . Progression free survival
time was determined by CA125 Resist based on serial
CA125 measurements, as well as on CT scans.

Immunoblot analysis
To prepare whole cell extracts, cells were
homogenized in RIPA buffer containing proteinase
inhibitors and centrifuged at 12,000 rpm for 15 min at
4°C. Cytoplasmic and nuclear cell extracts were prepared
[Nuclear and Cytoplasmic Extraction kit (Pierce #78833)]
and protein concentration of extracts was determined
[BCA Protein Assay Kit (Pierce #23225)]. Soluble
proteins were separated on 10% SDS-PAGE gels and
analyzed by Western blotting using antibodies toHuR
(1:1000) (clone 3A2; Santa Cruz Biotechnology), dCK
(1:500) (clone 2243C2; Santa Cruz), WEE1 (1:1000)
(clone B11; Santa Cruz), lamin A/C (1:1000) (clone 636;
Santa Cruz Biotechnology), or GAPDH (1:8000) (clone
5C6; Ambion). Blots were washed several times with
PBST (phosphate buffered saline, 0.1% Tween), then
incubated with horseradish peroxidase-labeled goat antimouse (1:8000) (Thermo Scientific) secondary antibody.
Proteins were visualized with ECL (Pierce #32106).
Densitometry quantification of proteins was done using
Image J software.

Generation of HuR knock-down cell lines
HuR stable knock-down cell lines were generated
in our lab as previously described [17]. Briefly, to
generate OVCAR5 cells stably-expressing shHuRc257
(“c” for constitutive) or shCtrl, cells were infected with
shHuRc257- or shCtrl-expressing lentivirus. Twentyfour hours after viral infection, shHuRc257- or shCtrlexpressing cells were selected in medium containing
hygromycin B (Gemini #400-123). To generate OVCAR3
Dox-inducible shHuRi699 cells (“i” for inducible), cells
were infected with shHuRi699-expressing lentivirus.
Forty-eight hours post-viral infection, shHuR- or shCtrlexpressing cells were selected in medium containing
puromycin dihydrochloride (Gemini # 400-128P).
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Immunostaining

and dCK expression, and HuR and WEE1 expression were
evaluated using Fisher’s exact test.

Antigen retrieval was performed on deparaffinized
tumor sections by steam heating for 30 min in citrate
buffer followed by endogenous peroxidase quenching
with 3% H2O2/methanol for 20 min. Cells were grown in
chamber slides, then fixed in cold acetone at -20°C for
10 minutes. Tumor sections or cells were incubated with
primary antibody and biotinylated secondary antibody.
Signals were amplified and visualized either using the
TSA-Plus Fluorescence System (Perkin Elmer) according
to manufacturer’s instructions, or using avidin/biotin
complex system (VECTASTAIN Elite ABC kit from
VECTOR Laboratories) followed by DAB visualization
and hematoxylin counterstaining. Slides were imaged
with a Zeiss Axiovert 200M microscope or Zeiss Axioplan
microscope. Human ovarian tumor HuR cytoplasmic
staining was scored as -, +/-, ++, or +++. Stained sections
were viewed and scored twice by two different pairs of
investigators (JAS and WP; JAS and GSD) who were
blind to PFS of each patient. Anti-HuR monoclonal
antibody 19F12 (1:5000) was from Clonegene. Anti-dCK
(Abcam #ab151966) was from Abcam. Anti-WEE1 (clone
B-11) was from Santa Cruz.
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